Hot Topics

AmeriPath has developed a new assay, JAK2 V617F Mutation Analysis, that detects and quantifies a mutation in the Janus kinase 2 (JAK2) gene common in bcr/abl-negative myeloproliferative disorders (MPDs). Read more.

AmeriPath Oncology, cancer information for optimal patient care, provides comprehensive diagnostic, prognostic and therapeutic information on hematopoietic and solid tumor malignancies. Highly experienced, board-certified pathologists and Ph.D.’s utilize an integrated, multidisciplinary approach and state-of-the-art technologies to better assist you in providing optimal and cost-effective patient care.

Test Menu Overview

Comprehensive evaluation of bone marrow and lymphoid specimens

• Diagnostic consultations
• Morphologic evaluation
• Flow cytometry immunophenotyping
• ZAP-70 flow cytometric analysis of B-cell CLL
• Cytogenetic karyotype analysis
• Immunohistochemistry (IHC)
• Fluorescence In Situ Hybridization (FISH) for genetic translocations
• JAK2 V617F Mutation Analysis by PCR
• Polymerase Chain Reaction (PCR) for gene rearrangements
• Hematopathology profiles

Evaluation of breast, prostate, colon, bladder and other cancer specimens

• Diagnostic Consultations
• Comprehensive immunohistochemistry
• Estrogen and progesterone receptor analysis
• HER-2/neu status evaluation utilizing IHC and FISH
• Proliferation (Ki-67) or suppressor gene (p53) analyses
• EGFR, pS2 and Cathepsin D prognostic markers
• DNA ploidy, S-phase and proliferation index analysis
• EGFR PharmDx™
• Image analysis utilizing Chromavision ACIS®
• HNPCC screening with DNA mismatch repair markers
• Lymph node micrometastasis detection
• Cytogenetic karyotype analysis
• ImmunoCyt™ and UroVysion™ bladder cancer monitoring

Detection of Infectious Agents

• High and low risk HPV by CISH (Chromogenic in situ Hybridization)
• High and low risk HPV by Hybrid Capture II®
• Chlamydia trachomatis by PCR
• Neisseria gonorrhea by PCR